What is Sales and Marketing Strategy of Evotec Company?

The primary Evotec sales strategy is executed by its global business development teams. They engage directly with pharmaceutical executives, biotech founders, and academic officers to forge strategic alliances.

A sophisticated digital presence, including its corporate website and investor portal, is vital for disseminating technical data. This channel generated over 70% of new strategic partnership discussions in 2024.

The company's Evotec business development model has evolved toward integrated joint ventures and shared-risk platforms like EVOconnect™. These ecosystems provide full access to Evotec's integrated drug discovery capabilities for equity and milestones.

Securing exclusive, multi-year collaborations is a cornerstone of the Evotec commercial strategy. The 2025 expansion of its partnership with Novo Nordisk, valued at over €350 million, exemplifies how this channel locks in future revenue.

The central brand message, 'Partnerships that Cure,' signifies a shift from a service provider to a deeply integrated, invested partner. This elevates the company's value proposition beyond simple transactional engagements, promising shared risk and reward. It directly appeals to pharmaceutical and biotech leaders seeking to de-risk their own R&D investments.

A clean, modern, and data-rich visual identity reinforces the brand's commitment to precision and scientific reliability. The tone of voice is consistently professional and confident, mirroring the serious nature of drug discovery. This consistency builds trust and credibility with a target audience of scientifically-driven decision-makers.

The brand's differentiation is built on three pillars: unparalleled integrated data capabilities, a unique equity-based partnership model, and a vast co-owned pipeline. This USP directly counters the industry's core challenges by offering increased probability of technical success and a more efficient path to market for partners.

This positioning powerfully resonates with its target audience of pharmaceutical and biotech leaders. It offers a tangible solution to the unsustainable economics of traditional drug discovery, promising not just services, but a fundamentally better partnership model for generating value and achieving success.

Launched in 2023, this campaign targeted top-tier biotechs with its EVOpan Hunting platform. The 'Unleash Your Target' concept successfully onboarded over 15 new partners, generating an estimated €80 million in committed funding and creating a pipeline of over 50 novel programs.

This 2024 strategic repositioning was marketed directly to investors to signal a deep commitment to neuroscience. The transformative deal extended the partnership to 2030, with BMS committing over $650 million in near-term payments, causing an immediate 8% stock surge.

This continuous campaign showcases end-to-end integrated biomanufacturing capabilities to secure major contracts. A key success was a $240 million partnership with Takeda in 2025 to develop and manufacture complex biologic drugs, a core part of its revenue streams.

Evotec's sales strategy for drug discovery relies on building deep, long-term strategic alliances with big pharma. This business development model is a key competitive advantage, as detailed in the Competitors Landscape of Evotec analysis.